These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2129413)

  • 61. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.
    von dem Borne PA; Meijers JC; Bouma BN
    Blood; 1995 Oct; 86(8):3035-42. PubMed ID: 7579397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment.
    Varjú I; Longstaff C; Szabó L; Farkas ÁZ; Varga-Szabó VJ; Tanka-Salamon A; Machovich R; Kolev K
    Thromb Haemost; 2015 Jun; 113(6):1289-98. PubMed ID: 25789443
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design and evaluation of a thrombin-activable plasminogen activator.
    Yang WP; Goldstein J; Procyk R; Matsueda GR; Shaw SY
    Biochemistry; 1994 Mar; 33(8):p606-12. PubMed ID: 8117652
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
    Guimarães AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
    Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of ultrasound on tissue-type plasminogen activator-induced thrombolysis.
    Lauer CG; Burge R; Tang DB; Bass BG; Gomez ER; Alving BM
    Circulation; 1992 Oct; 86(4):1257-64. PubMed ID: 1394932
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
    Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G
    Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
    Mukherjee P; Lyden P; Fernández JA; Davis TP; Pryor KE; Zlokovic BV; Griffin JH
    Stroke; 2020 Jul; 51(7):2236-2239. PubMed ID: 32568648
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Activated protein C accelerates clot lysis by virtue of its anticoagulant activity.
    de Fouw NJ; van Tilburg NH; Haverkate F; Bertina RM
    Blood Coagul Fibrinolysis; 1993 Apr; 4(2):201-10. PubMed ID: 8388739
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clot structure modification by fondaparinux and consequence on fibrinolysis: a new mechanism of antithrombotic activity.
    Varin R; Mirshahi S; Mirshahi P; Kierzek G; Sebaoun D; Mishal Z; Vannier JP; Yvonne Borg J; Simoneau G; Soria C; Soria J
    Thromb Haemost; 2007 Jan; 97(1):27-31. PubMed ID: 17200767
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction.
    Anand S; Diamond SL
    Circulation; 1996 Aug; 94(4):763-74. PubMed ID: 8772700
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro.
    Aisina R; Mukhametova L; Varfolomeyev S
    Biochim Biophys Acta; 2016 Apr; 1860(4):629-35. PubMed ID: 26723174
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
    Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
    Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
    Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME
    Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R; Li S; Gurewich V
    J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor.
    Lisman T; Adelmeijer J; Nieuwenhuis HK; de Groot PG
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):557-62. PubMed ID: 12960609
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds.
    Gadbut AP; Schullek JR; Hanel AM; MacAllan DR
    Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro.
    Zamarron C; Lijnen HR; Collen D
    Thromb Res; 1984 Aug; 35(3):335-45. PubMed ID: 6431630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.